BioSeek to Study Compounds for UCB | GenomeWeb
NEW YORK (GenomeWeb News) - BioSeek said today it has entered into an agreement with the Belgian biopharmaceutical company UCB to evaluate drug compounds.
 
Under the agreement, BioSeek will use its BioMAP systems to support target differentiation, lead development, and drug-candidate selection activities for UCB compounds in several target classes. UCB is focused on developing therapeutics for central nervous system disorders, inflammation, and oncology.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.